Recent research have centered on the overlap of GLP|GIP|glucagon receptor stimulant therapies and dopamine neurotransmission. While GLP agonists are commonly employed for managing type 2 T2DM, their emerging effects on reinforcement circuits, specifically governed by dopaminergic pathways, are attracting substantial attention. This report presen… Read More